Clinical Trial: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Advanced Solid Tumors

U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827613) titled 'A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Advanced Solid Tumors' on Jan. 28.

Brief Summary: This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Triple Negative ...